02-373-5 Me. Code R. § 1

Current through 2024-51, December 18, 2024
Section 373-5-1 - Definitions
1. Board.For purposes of this chapter, "Board" means the Maine Board of Pharmacy.
2.Collaborative drug therapy management."Collaborative drug therapy management" is defined in 32 MRS§13702-A(2-A). The statutory requirements for collaborative drug therapy management are set forth in 32 MRS §§13841 - 13847.
3.Collaborative practice agreement."Collaborative practice agreement" is defined in 32 MRS §13702-A(2-B).
4. Practitioner."Practitioner" is defined in 32 MRS §13702-A(29).
5. Qualifying condition."Qualifying condition" means a condition or disease with generally accepted standards of care, which may include, but is not limited to, the following examples:
A. Anticoagulation
B. Asthma
C. Diabetes
D. Dyslipidemia
E. Hyperlipidemia
F. Hypertension
G. Infectious Disease
H. Cancer
I. Thyroid Disorder
6. Treatment protocol."Treatment protocol," as referenced in 32 MRS §13845, means the written document by which the practitionerdescribes the activities of drug therapy management in which the pharmacist is authorized to engage under a collaborative practice agreement and specifies the procedures and parameters of that practice authority.
7. Unrestricted pharmacist license."Unrestricted pharmacist license" means a pharmacist license, the holder of which is not subject to any conditions of licensure affecting the scope of practice.

02-373 C.M.R. ch. 5, § 1